Experiment 908814

Worktypes

ANTICANCER AND/OR CYTOTOXICITY MARKER CODEPHARMACOLOGY OF COMPOUND - IN HUMANS

Compounds isolated

DIDEMNIN B

Details

PropertyValue
Pharmacology
ANTITUMOR ACTIVITY
Administration routeIV INFUSION
OrganismEmpty organism
CitationANON:. (1990). DIDEMNIN B.. 15(1)
Amount utilized
Compound isolated
Disease22 PATIENTS WITH SOLID TUMORS NOT RECEIVING PRE-CHEMOTHERAPY ANTIEMETICS WERE TREATED IN A PHASE I TRIAL. NO HEMATOLOGICAL OR BIOCHEMICAL TOXICITY WAS OBSERVED. SIDE EFFECTS INCLUDED NAUSEA, VOMITING, LOCAL SKIN REACTIONS, TIREDNESS, ANOREXIA, DIARRHEA AND ALLERGY TO DRUG VECHICLE CREMOPHOR-EL. MAXIMAL TOLERATED DOSE WAS 1.0 MG PER SQ. M.
Dose amountVAR
Number2
Qualitative result.
AnimalHUMAN ADULT
Dose expressionDOSE